Unknown PHASE2 INTERVENTIONAL 1-arm NCT04684017

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer: A Single Arm Phase II Trial

Sponsor: Shanghai Chest Hospital

Conditions Anlotinib SCLC

Interventions Anlotinib hydrochloride Carboplatin Etoposide

Updated 4 times since 2021 Last updated: Dec 22, 2020 Started: May 1, 2019 Primary completion: Sep 1, 2021 Completion: Jan 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anlotinib and SCLC and is currently ongoing. Shanghai Chest Hospital leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE2

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Chest Hospital

Data source: Shanghai Chest Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China